Related Experiment Video
Updated: Aug 14, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Antibiotic treatment of community acquired bacterial meningitis
1Department of Pediatrics, University of New Mexico, Albuquerque.
Abstract:
Community acquired meningitis is predominantly caused by three agents: Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis Four physical properties of available drugs--molecular size, protein binding, lipid solubility and ionization--affect drug entry to the central nervous system (CNS). These factors, coupled with acute changes in blood-brain barriers and intrinsic bactericidal activity, have a bearing on the success of treatment with all agents. Third generation cephalosporins have largely supplanted older regimens due to their intrinsic qualities of greater bactericidal activity, optimal cerebrospinal fluid pharmacokinetics, and low toxicity. The pharmacological principles of treatment of CNS bacterial infections, pharmacology of available drugs, and current treatment recommendations are reviewed.
Insights
Community acquired meningitis treatment relies on understanding drug properties for central nervous system (CNS) entry. Third-generation cephalosporins are preferred for bacterial meningitis due to superior efficacy and safety.
Area of Science:
- Pharmacology
- Infectious Diseases
- Neuroscience
Background:
- Community acquired meningitis is primarily caused by Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis.
- Drug penetration into the central nervous system (CNS) is influenced by molecular size, protein binding, lipid solubility, and ionization.
- Treatment success depends on drug properties, blood-brain barrier status, and bactericidal activity.
Purpose of the Study:
- To review the pharmacological principles guiding the treatment of bacterial meningitis.
- To discuss the pharmacology of drugs used for central nervous system infections.
- To present current treatment recommendations for community acquired meningitis.
Main Methods:
- Review of existing literature on meningitis treatment.
- Analysis of pharmacokinetic properties of antimicrobial agents.
- Evaluation of drug efficacy and safety profiles.
Main Results:
- Third-generation cephalosporins demonstrate enhanced bactericidal activity compared to older treatments.
- These agents exhibit optimal cerebrospinal fluid (CSF) pharmacokinetics.
- Third-generation cephalosporins are associated with low toxicity.
Conclusions:
- Understanding drug properties is crucial for effective CNS infection treatment.
- Third-generation cephalosporins represent a significant advancement in managing bacterial meningitis.
- Current recommendations favor third-generation cephalosporins for their favorable pharmacological profile.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Bacterial Meningitis
Mechanism of Antibiotic Resistance in MRSA
Viral Meningitis
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology

